{"id":49743,"date":"2022-10-18T14:10:10","date_gmt":"2022-10-18T12:10:10","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/"},"modified":"2022-10-18T14:10:10","modified_gmt":"2022-10-18T12:10:10","slug":"oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/","title":{"rendered":"Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical Advisor"},"content":{"rendered":"<div>\n<p>CHICAGO&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/AI?src=hash\" target=\"_blank\" rel=\"noopener\">#AI<\/a>&#8212;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.physiq.com&amp;esheet=52946491&amp;newsitemid=20221018005214&amp;lan=en-US&amp;anchor=physIQ&amp;index=1&amp;md5=5fc126f905afb813074ad065fe9514ac\" rel=\"nofollow noopener\" shape=\"rect\">physIQ<\/a> announced today that Jason Luke, MD, FACP, a recognized expert in immuno-oncology, professor of medicine, and clinical practitioner has been appointed to the company\u2019s Medical Advisory Board. In this role, Dr. Luke will provide expert medical counsel for physIQ\u2019s ongoing development of solutions to aide in oncology treatments, including physIQ\u2019s development of digital biomarkers for inflammation.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221018005214\/en\/1604332\/5\/physIQ-2022-Logo-2Colors-RGB-Web.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221018005214\/en\/1604332\/21\/physIQ-2022-Logo-2Colors-RGB-Web.jpg\"><\/a><\/p>\n<p>\n\u201cDr. Luke brings extensive immuno-oncology expertise to physIQ that will provide immeasurable insight into our work on inflammation and oncology treatments,\u201d said Steve Steinhubl, MD, physIQ\u2019s Chief Medical Officer. \u201cAs a practicing physician and researcher, he brings the vision, experience, and empathy that we embrace at physIQ.\u201d\n<\/p>\n<p>\nOne of Dr. Luke\u2019s first projects with physIQ is to serve as principal investigator on a clinical study designed to show how physIQ\u2019s Inflammatory Multivariate Change Index (iMCI) can make CAR-T, a ground-breaking oncology treatment, safer and more accessible by enabling real-time in-home safety monitoring post CAR-T dosing. Dr. Luke is the Director of the Immunotherapy and Drug Development Center at the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center and Associate Professor at the University of Pittsburgh. He focuses on translational therapeutic advances in immuno-oncology, early phase drug development for advanced solid tumors and the management of patients with cutaneous malignancies.\n<\/p>\n<p>\nIn melanoma, Dr. Luke has designed and led two practice changing studies documenting the role of combination anti-PD1 + low dose anti-CTLA4 Ab in PD1 refractory disease, as well as establishing the role for, and FDA\/EMA approval of, adjuvant anti-PD1 for stage IIB\/C melanoma. More generally, Dr Luke has been a lead investigator for clinical trials of many novel immunotherapies in advanced solid tumors. He has been a major contributor toward the investigation of radiation and the microbiome in relation to cancer immunotherapy.\n<\/p>\n<p>\nDr. Luke\u2019s translational research laboratory focuses on biomedical and bioinformatic approaches to advance cancer immunotherapy. Dr. Luke is an At Large member of the Board of Directors for SITC and has held leadership roles in SMR, AACR &amp; ASCO. Dr Luke is the PI or Project leader for multiple funding mechanisms including R01, UM1, P50 &amp; multiple state or private grants.\n<\/p>\n<p>\nDr. Luke received his medical degree from Rosalind Franklin University of Medicine and Science\/Chicago Medical School in North Chicago. He completed an internship and residency in internal medicine at Boston University Medical Center and fellowships in medicine and medical oncology at Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York.\n<\/p>\n<p>\n<b>About physIQ<\/b>\n<\/p>\n<p>\nphysIQ delivers personalized medical predictions that vastly improve patient outcomes. By combining proprietary AI and any wearable biosensor to continuously monitor patients in real-world settings, physIQ is advancing medicine and enabling clinical trial sponsors and clinicians to proactively detect physiological decompensations, improve the safety and efficacy of new therapies and speed time to market, and deliver personalized clinical interventions to improve patient outcomes. For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.physIQ.com&amp;esheet=52946491&amp;newsitemid=20221018005214&amp;lan=en-US&amp;anchor=www.physIQ.com&amp;index=2&amp;md5=84c4eacbaf3c52b2522cbc46f976c6de\" rel=\"nofollow noopener\" shape=\"rect\">www.physIQ.com<\/a>. Follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FPhysIQ&amp;esheet=52946491&amp;newsitemid=20221018005214&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=85841e1283808fcf9485ca05b4041d31\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fphysiq&amp;esheet=52946491&amp;newsitemid=20221018005214&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=52fcc5c18fc93e56d40a34824dd66378\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nStaci Rubinstein<br \/>\n<br \/>Outlook Marketing Services, Inc.<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;&#58;&#x73;&#116;&#x61;&#99;&#x69;&#64;&#x6f;&#117;&#x74;&#108;&#x6f;&#111;&#x6b;&#109;&#x61;&#114;&#x6b;&#101;&#x74;&#105;&#x6e;&#103;&#x73;&#114;&#x76;&#46;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x73;&#x74;&#x61;&#x63;&#x69;&#x40;&#x6f;&#x75;&#x74;&#x6c;&#x6f;&#x6f;&#x6b;&#x6d;&#x61;&#x72;&#x6b;&#x65;&#x74;&#x69;&#x6e;&#x67;&#115;&#114;&#118;&#46;&#99;&#111;&#109;<\/a><br \/>847-549-0712\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>CHICAGO&#8211;(BUSINESS WIRE)&#8211;#AI&#8212;physIQ announced today that Jason Luke, MD, FACP, a recognized expert in immuno-oncology, professor of medicine, and clinical practitioner has been appointed to the company\u2019s Medical Advisory Board. In this role, Dr. Luke will provide expert medical counsel for physIQ\u2019s ongoing development of solutions to aide in oncology treatments, including physIQ\u2019s development of digital &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49743","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical Advisor - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical Advisor - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CHICAGO&#8211;(BUSINESS WIRE)&#8211;#AI&#8212;physIQ announced today that Jason Luke, MD, FACP, a recognized expert in immuno-oncology, professor of medicine, and clinical practitioner has been appointed to the company\u2019s Medical Advisory Board. In this role, Dr. Luke will provide expert medical counsel for physIQ\u2019s ongoing development of solutions to aide in oncology treatments, including physIQ\u2019s development of digital ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-18T12:10:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221018005214\/en\/1604332\/21\/physIQ-2022-Logo-2Colors-RGB-Web.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical Advisor\",\"datePublished\":\"2022-10-18T12:10:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\\\/\"},\"wordCount\":517,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018005214\\\/en\\\/1604332\\\/21\\\/physIQ-2022-Logo-2Colors-RGB-Web.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\\\/\",\"name\":\"Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical Advisor - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018005214\\\/en\\\/1604332\\\/21\\\/physIQ-2022-Logo-2Colors-RGB-Web.jpg\",\"datePublished\":\"2022-10-18T12:10:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018005214\\\/en\\\/1604332\\\/21\\\/physIQ-2022-Logo-2Colors-RGB-Web.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018005214\\\/en\\\/1604332\\\/21\\\/physIQ-2022-Logo-2Colors-RGB-Web.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical Advisor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical Advisor - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/","og_locale":"en_US","og_type":"article","og_title":"Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical Advisor - Pharma Trend","og_description":"CHICAGO&#8211;(BUSINESS WIRE)&#8211;#AI&#8212;physIQ announced today that Jason Luke, MD, FACP, a recognized expert in immuno-oncology, professor of medicine, and clinical practitioner has been appointed to the company\u2019s Medical Advisory Board. In this role, Dr. Luke will provide expert medical counsel for physIQ\u2019s ongoing development of solutions to aide in oncology treatments, including physIQ\u2019s development of digital ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-18T12:10:10+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221018005214\/en\/1604332\/21\/physIQ-2022-Logo-2Colors-RGB-Web.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical Advisor","datePublished":"2022-10-18T12:10:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/"},"wordCount":517,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221018005214\/en\/1604332\/21\/physIQ-2022-Logo-2Colors-RGB-Web.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/","url":"https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/","name":"Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical Advisor - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221018005214\/en\/1604332\/21\/physIQ-2022-Logo-2Colors-RGB-Web.jpg","datePublished":"2022-10-18T12:10:10+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221018005214\/en\/1604332\/21\/physIQ-2022-Logo-2Colors-RGB-Web.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221018005214\/en\/1604332\/21\/physIQ-2022-Logo-2Colors-RGB-Web.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/oncology-clinician-scientist-jason-luke-md-named-physiq-medical-advisor\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical Advisor"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49743"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49743\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}